Härmed en kort fråga som jag skickar iväg med en perfekt skruvad innervrist. Ilsket kraftpass´till EpiCepts Corporations Vd Jack Talley:
AML (Acute Myloid Leukemia) är en cancerdiagnos bara djävulen kan annat än avsky, som skräckmonstret itsel.
Jack Talley - ni ser honom på bild intill - har rattat EpiCept duktigt och en hoppets låga sakta tänts hos de äldre - det handlar främst om just äldre drabbade----vilket i lite större tänkande än just nuets tid och rum=status även i dödsrikets salar---och det är läkemedlet CEPLENE--- av EMEA /The European Medicine Agency/.
godkänt och officiellt rankat som ett av 12 (av 65 totalt godkända senaste året) "med en positiv efffekt för folkhälsan".Europa ligger därmed öppet för att dess AML-offer utan fler dröjsmål skall kunna beställa behandling.
Och uppleva en möjlighet att slippa återfall i leukemi-pinan!
Men när EpiCept beskrev resultat/händelser det tredje kvartalet 2009 så blev den
stora frågan utan svar; Hur många har det sedan juni den engagerade brittiska läkemedels-agenten IDIS lyckats nå med CEPLENE? 1-2-3? 1000 patienter? Läkare och patienter, med anhöriga etc etc, måste ju veta att EMEA GODKÄNT CEPLENE?
För mig är det en gåta att inte en högeffektiv punktinsats satts in i den godkända jättemarknaden EU MED 360 MILJONER MÄNNISKOR...varav beräknas 25 000 just i denna stund vara AML-DÖMDA till säker död.Per år kommer lika många...
USA har ännu ej påbörjat examinationen av CEPLENE.Ett förberedande, positivt sammanträde har avverkats. Godkännandet kommer.
Kanske sker det 2010. Kanske dröjer det till första halvåret 2011.
Under tiden ligger nästan hela världen spelklar för CEPLENE-behandling.Och resten av världen; flera miljarder innevånare bör ha samma rätt till botemedel.
Thorwald
Fran igar:
SvaraRaderaBristol-Myers Squibb Co. (BMY) reached an agreement that could result in the
company paying more than $1 billion for exclusive rights to develop and
commercialize a rheumatoid arthritis treatment developed by privately held
Alder Biopharmaceuticals Inc.
Big drug companies have increasingly teamed with smaller firms to boost their
pipelines after a string of failures and the ever-increasing costs of drug
development. But in contrast to rivals that have tried to diversify their
businesses or pursue mega-mergers, Bristol has chosen to hone its focus on
prescription drugs, selling off assets and using the proceeds to build up its
research pipeline.
Bristol will pay $85 million upfront, with potential development and
regulatory milestone payments of as much as $764 million, potential sales
milestone payments of more than $200 million, and sales royalties. Alder has
the option to require Bristol-Myers to take a stake of up to $20 million in
Alder if it holds an initial public offering.
Nar skall de lagga ett bud pa Epicept? Kanske efter Azixa-resultaten?
En annan tanke: Vilket stort BP har haft forandringar i ledningen och ar nu ater intresserade av avtal rorande Ceplene??
Kanske ar det Novartis?
http://www.novartis.com/newsroom/media-releases/en/2009/1314149.s html
"Symonds joins Novartis from Goldman Sachs starting September 1, 2009.
Symonds, 50, spent eight years as CFO at AstraZeneca, where his position encompassed Finance, M&A, Strategy, IT, Purchasing, Business Development and Licensing. Before that he was Finance Director at Zeneca and previously was a partner at KPMG".
Kanske Symonds och Bernhard Tyrell ar gamla polare fran Astra Zeneca-tiden??
bulgo---and of course all others as well:
SvaraRaderaThis is remarkable uncleared;
Put the finger on the human rights
for a moment and distance you from the fauna of money-hunters:
Isn´t there a very misconduct made
vs. Professor Kristoffer Hellstrands outstanding skill which are - and there should NO doubts! -, after 25 years of hard, stubborncolored, intellligent
work we have Ceplene. If you believein your mantra "Together we will prevail..." you must be prepared to think a little bit widerr vs.drugs; Ceplene and AML is exclusive---should be valued in the megadivision---actually in the same uniqe category as Levedopa (Madopark, Sinemet)---created by Hellstrands mentor, Arvid Carlsson, 86.
I want, bulgo, that you alson send this stuff to Jack Talley /and Bernie/---and CEO Cornelius Bristol Myers Squibb. When Iread Avanza Forum I feel like I´m trapped in nowhere but in the same time chaos.
Thorwald
Fick svar fran Epicept:
SvaraRaderaFrån: "Robert Cook"
Datum: Thu, 12 Nov 2009 15:47:55 -0500
"The Named Patient Program was not intended to be a commercial sales and marketing program. It is essentially a compassionate use program that exists to allow patients to use the drug prior to its commercial availability. For that reason we did not provide any sales forecasts. We are endeavoring to increase awareness of Ceplene among European hemotologists prior to commercial launch, which we believe will foster additional use.
It is very important that any long term license agreement provide fair compensation to the Company. While it’s taking longer than anticipated to complete a deal, we will not license Ceplene in a deal with unattractive terms.
Our NP-1 partnership efforts commenced in 2009 after we received the data for the Phase II PHN trial. Data from the Phase II DPN trial was received in 2007. Data from both of these trials were positive and were required to interest potential partners".
Bob Cook